新的P2Y12抑制剂在冠状动脉疾病中的应用

摘要

在新的P2Y12受体拮抗剂中,普拉格雷对于糖尿病、ST段抬高型心肌梗死、冠状动脉支架、近期心血管事件的抗栓治疗方面优于氯吡格雷;对于ST段抬高型心肌梗死和非ST段抬高型心肌梗死患者预防主要心血管事件的有效性和安全性方面,替卡格雷均优于氯吡格雷;依诺格雷是一种直接作用、可逆性的P2Y12抑制剂,较氯吡格雷有更好的抗血栓作用,且出血发生率同安慰剂.%Among new P2Y12 inhibitors, peasugrel was a more effective antithrombotic drug than clopidogrel in patients with diahetes mellitus , ST-elevation mvocardial infarction , coronary stents , or recurrent cardiovascular events on treatment. Efficacy and safety of ticagrelor for the prevention of major adverse cardiac events ( MACEs ) in patients with non-ST-elevation or ST-elevation acute coronary syndrome was better than clopidogrel. Elinogrel was a direct-acting and reversible platelet P2Y12 receptor antagonist. It has better effective antithrombotic than clopidogrel . The incidence of bleeding events was infrequent and appeared to he similar in patients treated with different doses of elinogrel versus placebo.